Update on antibody–drug conjugates: where are we now, & where are we going?
Immuno-Oncology Insights 2022; 3(5), 195 –198
DOI: 10.18609/ioi.2022.022
Published: 16 April 2022
Viewpoint
Fernanda Arnaldez
“Antibody–drug conjugates are an expanding and
promising market segment, as they offer a canvas
for innovation almost in any single aspect of their
design and development.”
 copy.jpg)